In the spring of 2025, AbbVie’s leadership sat down to make a decision that must have felt simultaneously obvious and uncomfortable. The obesity drug market — dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, built around a class of drugs called GLP-1 receptor agonists — was already producing billions in annual revenue and growing faster than almost anything else in pharmaceuticals.
It did not include AbbVie, a North Chicago-based company well-known for its immunology portfolio and Humira. Not one. And the window to enter wasn’t going to stay open indefinitely. In an attempt to predict that the next wave of obesity treatments would differ significantly from the current one, the company wrote a $350 million check to a small Danish biotech company called Gubra.
Key Facts: AbbVie’s $350M Amylin Obesity Bet
| Deal announced | March 3, 2025 — AbbVie (NYSE: ABBV) licenses GUB014295 from Gubra A/S (Copenhagen: GUBRA) |
| Drug name | GUB014295 / ABBV-295 (also called GUBamy) — a long-acting amylin analog; activates both amylin and calcitonin receptors |
| Deal value | $350 million upfront + up to $1.875 billion in milestone payments + tiered royalties on global net sales |
| Early Phase 1 results | Weight loss of 7.75%–9.79% (least-squares mean) at week 12 across weekly dosing cohorts; no serious adverse events reported |
| Mechanism of action | Amylin analog — stimulates satiety signals in the brain, reduces food intake, delays gastric emptying; designed to resist “fibrillation” that weakens rival amylin drugs |
| Key competitors | Novo Nordisk (cagrilintide/CagriSema — Phase 3), Eli Lilly (eloralintide — Phase 2, 11.3% loss at 12 weeks), Zealand Pharma (Phase 2), AstraZeneca, Metsera |
| Market size | Global obesity drug market projected to exceed $173.5 billion by 2031; nearly 900 million adults globally affected |
| About AbbVie | North Chicago, IL — primarily known for immunology (Humira), oncology, neuroscience, and Allergan aesthetics; obesity is a new strategic pillar |
| About Gubra | Founded 2008, Hørsholm, Denmark — ~260 employees; specializes in peptide-based drug discovery for metabolic and fibrotic diseases |
| Reference | AbbVie News Center — Official Announcement |
The drug at the center of that bet is called ABBV-295 — a long-acting amylin analog, meaning it mimics amylin, a hormone secreted by the pancreas alongside insulin that signals fullness to the brain, slows digestion, and suppresses appetite. Although amylin has long been recognized as a therapeutic target in obesity research, it has proven technically challenging to produce a stable, injectable form. Amylin-targeting molecules tend to undergo a chemical process called fibrillation — essentially clumping and degrading — which reduces their potency and raises safety concerns. AbbVie was drawn to Gubra’s medication in part because of its stability claim, which was specifically designed to withstand that process. It’s still unclear if it fulfills that promise at higher dosages and over longer trial periods.
In March 2026, AbbVie published Phase 1 multiple-ascending dose results that demonstrated weight loss in cohorts receiving weekly injections ranging from 7.75 percent to 9.79 percent at twelve weeks. This was the first real data. According to the company, the tolerability was favorable at all dose levels, with only mild and concentrated gastrointestinal side effects during the first six weeks of treatment and no significant adverse events.
William Blair analysts described the initial results as encouraging and competitive across the Amylin class. Because twelve weeks is a short time frame and Phase 1 trials in lean to slightly overweight men are not where obesity medications succeed or fail, the final phrase—”initial update”—is doing significant work. Later on, the true test will take place.
As this market develops, it seems like everyone in the pharmaceutical industry is currently making calculations regarding amylin. Novo Nordisk already has Phase 3 data on its amylin drug cagrilintide, tested both alone and in combination with Wegovy in a formulation called CagriSema. Last year, observers were impressed by Eli Lilly’s amylin analog, eloralintide, with weight loss as high as 11.3 percent at twelve weeks; AbbVie’s results are comparable to but fall short of this benchmark.
Zealand Pharma is in Phase 2. Similar agents are being developed by Metsera and AstraZeneca. In just two years, the amylin space has transformed from a promising field of study to one of the busiest areas of drug development worldwide. AbbVie is arriving after most of the others — a position that requires either a meaningfully differentiated drug or a very patient capital strategy.
It’s important to comprehend the strategic context surrounding this wager. GLP-1 medications have been a problem for AbbVie’s Allergan aesthetics division, which includes Botox and other cosmetic injectable treatments, according to company executives.
The theory, supported by some early data, is that patients on weight-loss injections have less disposable income available for elective cosmetic procedures, a share-of-wallet effect that has been showing up in aesthetics revenue. Therefore, it wasn’t just an offensive move to enter the obesity market. There’s a defensive logic to it: if the GLP-1 wave is going to take money out of aesthetics, AbbVie may as well be capturing some of it on the drug side.
The partnership with Gubra gives AbbVie full global development and commercialization rights in exchange for up to 2.2 billion dollars in total payments including milestones and royalties — a structure that rewards Gubra handsomely if the drug works, and limits AbbVie’s immediate exposure if it doesn’t.
Founded in 2008 in Hørsholm, Denmark, Gubra focuses on peptide-based drug discovery and employs roughly 260 people. Before beginning to build its own pipeline, the company established its reputation through contract research. Its most sophisticated proprietary asset was the GUB014295 program, and the AbbVie acquisition is a liquidity event that simultaneously provides the Danish biotech with a significant commercial partner and financial stability.
It’s still unclear whether ABBV-295 will prove genuinely differentiated from the growing field of amylin analogs, or whether the stability advantage Gubra engineered will translate into clinically meaningful benefits over longer trials. The Phase 2 study, which analysts expect to launch later this year, will start answering those questions. With a mechanism different from GLP-1s, data that appears promising but not definitive, and the resources to stay in the race long enough to find out, AbbVie is currently making a calculated entry into the most competitive drug category in recent memory.
